Prior authorization expectation — therapies unproven and not medically necessary

For Tennessee Medicaid/CoverKids, prolotherapy and platelet-rich plasma (PRP) are classified as unproven and not medically necessary for any condition or indication; requests for these services are therefore expected to be denied absent compelling justification or plan-specific terms that override this stance.

Prior authorization recommended for DPT/PRP injectables

Consider prior authorization when requesting dextrose prolotherapy (DPT), PRP, or other injectable biologic therapies for knee osteoarthritis or chronic lateral epicondylitis; authorization requests should include documentation that supports the clinical indication and prior treatments.

Require documentation of prior conservative (refractory therapy) trial

Prior authorization requests should include evidence of prior first-line conservative care (e.g., structured home exercise, physical therapy, splinting) and a clinical rationale for proceeding to prolotherapy or PRP in refractory cases.

Prior authorization advised for PRP/prolotherapy due to heterogeneity

When PRP or prolotherapy is proposed, prior authorization is advised because heterogeneity of evidence and lack of standardized preparations justify review with supporting documentation of indication, prior therapies, and product/protocol details.

Require detailed PRP/procedure protocol and failed conservative therapy

Prior authorization requests should require documentation of failed conservative therapy, the specific PRP preparation and injection protocol (including leukocyte content, concentration, volume), target tissue/diagnosis and severity, and the intended number and timing of injections.

Prior authorization for PRP injections — require indication, prior treatments, and PRP details

Because evidence across indications is heterogeneous and generally low to very low certainty, prior authorization should require documentation of the indication, prior treatments attempted/failed, and specific PRP/preparation details to justify medical necessity.

Require documented clinical rationale with prior authorization

Evidence reviews frequently note inconsistent results and lack of standardized PRP protocols; prior authorization should record the documented clinical rationale and expected benefits given this uncertainty.

Prior authorization likely for OA / advanced arthritis — follow society guidance

Specialty society statements find evidence insufficient or recommend against routine PRP in advanced hip/knee arthritis and for knee/hip OA; prior authorization is likely for OA and advanced arthritis to confirm indication, prior conservative therapy, and potential enrollment in trial/registry where applicable.

No explicit prior authorization codes listed — use standard PA process

The policy does not list specific prior authorization CPT/HCPCS codes or unique prior authorization procedures; use the plan's standard prior authorization processes and reference the applicable procedure codes when submitting requests.

Stepwise care — require conservative modalities before injectables

Evidence often compares prolotherapy to exercise, saline, or physiotherapy; consider a stepwise approach requiring prior conservative modalities such as structured exercise or physiotherapy before approving advanced injectables.

Expect trial of exercise/physical therapy before injectables

Many trials administered prolotherapy alongside or after exercise programs; prior authorization or plan rules may require a documented trial of structured exercise/physical therapy before DPT is approved.

Conservative therapy first — PRP considered only after conservative care fails

Evidence reviews recommend conservative therapies (oral medications, physical therapy) before considering PRP; PRP is generally considered when conservative therapies are contraindicated or have failed.

Step therapy suggestion — failure/contraindication of standard treatments required

Require documentation that standard conservative treatments (physical therapy, NSAIDs, activity modification, and, where appropriate, corticosteroid or hyaluronic acid injections) have failed or are contraindicated before PRP or prolotherapy is authorized.

Step therapy expectation for tendinopathies — conservative measures required first

For tendinopathies (e.g., lateral epicondylitis, plantar fasciitis), consider requiring failure of standard conservative measures including physical therapy, NSAIDs, activity modification, and, when appropriate, a trial of corticosteroid injection prior to PRP.

Conservative comparators commonly used before PRP

Comparators in trials include corticosteroid, lidocaine, and standard wound care; many studies used these nonbiologic therapies before or instead of PRP, supporting their role as usual comparators and first-line options.

Require conservative therapy first per ASIPP guidance

ASIPP guidance indicates regenerative therapies may be provided in conjunction with structured exercise and appropriate conventional care; payers may require evidence of prior conventional therapy before approving biologic injections.

Coding reference — include listed procedure/HCPCS/CPT codes on claims

When submitting claims, reference the listed procedure and HCPCS/CPT codes (e.g., 0232T, G0460, G0465, M0076, P9020); listing does not imply coverage and may affect adjudication.

Required clinical documentation — diagnosis severity, baseline scores, prior therapies

Clinical documentation should include diagnosis severity (for KOA, Kellgren-Lawrence grade 2–3 when applicable), baseline pain scores (e.g., VAS), prior conservative therapies tried, injection type/concentration/site, number of planned sessions, and planned follow-up outcome measures (WOMAC, OKS, PPT) to support effectiveness claims.

Suggested documentation elements — diagnosis, prior response, protocol, outcome measures

Suggested documentation elements include the specific diagnosis (e.g., lateral epicondylitis, rotator cuff tendinopathy, TMJ disorder), prior conservative therapy and response, dextrose concentration and injection protocol (for DPT), and planned outcome measures (VAS, DASH/QuickDASH, SPADI, PRTEE).

Suggested clinical documentation elements — objective measures and protocol details

Studies frequently used objective clinical measures such as maximal incisal/mouth opening (MIO/MMO), VAS pain scores, and clearly documented injection protocols and number of injections; include these objective baseline and follow-up measures when available.

Required documentation elements — indication, prior therapy, PRP prep and injection plan

Required documentation elements for authorization should include the specific indication and grade/stage, prior conservative therapies attempted and their outcomes, PRP preparation method (leukocyte-rich vs leukocyte-poor, concentration, volume), number and timing of injections, use of imaging guidance, and counseling about possible post-injection pain.

Required clinical documentation elements — include PRP preparation and outcome measures

Evidence summaries emphasize heterogeneity in PRP preparation and inconsistent reporting of adverse events; required clinical documentation should therefore include PRP preparation method, number/volume of injections, targeted diagnosis, prior conservative therapies tried, and objective baseline and follow-up outcome measures (e.g., VAS, AOFAS, ODI).

Document PRP composition and selection (platelet/WBC counts, activation)

Document PRP composition when available (platelet and white blood cell counts, activation method) and the rationale for selecting a leukocyte-rich vs leukocyte-poor preparation, since many studies lacked these details and reviewers often cite this omission.

Research/governance documentation for knee OA — enroll in governance/audit when applicable

For knee osteoarthritis, document whether PRP use is within a research, clinical governance, or audit arrangement and include informed consent reflecting uncertainty of long-term benefit and potential harms per NICE recommendations.

Benefit plan governance — plan terms govern final coverage

When deciding coverage or approving requests, reference applicable federal, state, or contractual benefit plan terms; the Medical Policy is informational and plan-specific terms govern final coverage decisions.

Coverage denial trigger — therapies unproven and not medically necessary

Prolotherapy and PRP are explicitly listed as unproven and not medically necessary for any condition or indication; absent documented, compelling, indication-specific evidence and conformity with plan terms, denial of coverage is a likely outcome.

Evidence limitations may prompt denial — heterogeneous designs and techniques

Heterogeneous study designs, variable injection techniques and concentrations, and limited high-quality evidence are recurring limitations that may prompt denial or requests for further justification supporting medical necessity.

Evidence gaps affecting authorization — small/short trials and limited comparators

Lack of well-designed comparative studies, small sample sizes, heterogeneous populations, and short follow-up durations reduce certainty of benefit and may result in denial when robust long-term effectiveness or comparative data are required.

Standardization and efficacy concerns — lack of standardized PRP prep may trigger denial

Because PRP preparations are not standardized and efficacy/safety data are inconsistent (including trials showing no difference vs saline), reviewers may deny coverage or require strong justification when preparation or outcome data are not provided.

Heterogeneous evidence may trigger denial — variable protocols and reporting

Heterogeneous PRP preparation, injection methods, and variable number/timing of injections are cited repeatedly; absence of protocol standardization and missing documentation on preparation may lead to authorization denial.

Safety signal — higher post-injection pain and NNH ~13 for PRP (foot/ankle)

Systematic reviews of foot and ankle PRP trials report higher rates of post-injection pain and calculate a number needed to harm of 13 for PRP; this safety signal (injection-site pain) may influence medical necessity determinations.

Uncertain protocols — absence of optimal PRP methods may lead to denial

Uncertain and heterogeneous PRP protocols and unclear optimal preparation/application increase uncertainty about which patients benefit; lack of protocol clarity in documentation may lead to coverage denial.

Wound indication risk — inconclusive evidence may prompt denial

Evidence for autologous PRP in chronic wounds is inconclusive and often low quality; for wound indications outside limited DFU findings, lack of strong evidence may trigger coverage denial.

Knee OA governance requirement — use only under governance/research arrangements

NICE recommends PRP for knee osteoarthritis only with special arrangements for governance, consent, and audit or research; absence of such arrangements or documentation may result in noncoverage.

Plan terms govern — contractual/federal/state rules determine coverage

Coverage decisions must follow federal, state, or contractual benefit plan terms; if plan terms do not permit coverage for these unproven therapies, requests will be denied regardless of clinical documentation.